MAGE-A3 peptide vaccine

MAGE-A3 peptide vaccine is a peptide-based cancer immunotherapy designed to stimulate the immune system to recognize and destroy tumor cells expressing the Melanoma-associated antigen 3 (MAGE-A3). MAGE-A3 is a tumor-associated antigen, specifically a cancer/testis antigen, that is frequently overexpressed in various malignancies such as melanoma and non-small cell lung cancer (NSCLC), but is absent in normal adult tissues except for immunoprivileged germ-line cells. The vaccine typically consists of synthetic peptides representing specific HLA-restricted epitopes of the MAGE-A3 protein. These peptides are intended to be processed and presented by major histocompatibility complex (MHC) molecules, thereby activating MAGE-A3-specific CD8+ cytotoxic T lymphocytes (CTLs) and CD4+ helper T cells. Clinical development has explored various formulations, including peptides emulsified with adjuvants like incomplete Freund's adjuvant or pulsed onto dendritic cells. Although early-phase trials demonstrated the induction of specific immune responses, the large-scale Phase 3 MAGRIT trial for a related MAGE-A3 recombinant protein vaccine failed to meet its primary endpoints, leading to the termination of major development programs for MAGE-A3-targeted vaccines.

Other names

MAGE-3 peptide vaccineMAGE3 peptide vaccineMAGE 3 peptide vaccineMAGE-A3 vaccineMAGE-A-3 vaccineMAGE-A 3 vaccineMAGE-3 vaccineMAGE3 vaccineMAGE 3 vaccineMAGE-A3 peptideMAGE-A-3 peptideMAGE-A 3 peptide